Movement Disorders

Self-administration of the drug led to statistically significant motor status changes within 30 minutes of treatment.

These data confirm the need for consideration of these costs when prescribing treatments, and is of considerable importance as out of pocket costs continue to rise in the US.

The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).

This novel trial’s positive outcome suggests that a multidisciplinary outpatient model is possible to integrate into care beyond just those who are most vulnerable in institutional care.

Final results of the EASE LID 2 study suggest that amantadine (Gocovri; Adamas) extended-release capsules are safe and effective over a 2-year treatment period.

The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis.

The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis.

The FDA has approved the investigational new drug application for AV-101 for the treatment of dyskinesia in patients with Parkinson disease who are treated with levodopa.

Join NeurologyLive and the Women Neurologists Group on Twitter to celebrate women in neurology on National Women Physicians Day.

The Infinity DBS system is the only directional DBS system approved to target all major areas associated with movement disorders, including Parkinson disease and essential tremor.

The phase 2 clinical trial of CAD-1883 will assess the efficacy and safety of the drug compared to placebo.

Neurology News Network for the week ending January 27, 2020.

Findings from the small-scale study showed that the drug had target engagement with β-glucocerebrosidase as well as cerebrospinal fluid penetration.